Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 46.30 - 69.86
Open     -
Vol / Avg. 0.00/6.04M
Mkt cap 113.85B
P/E 50.72
Div/yield 0.37/2.17
EPS 1.35
Shares 1.66B
Beta 0.27
Inst. own 73%
Jul 22, 2015
Q2 2015 Bristol-Myers Squibb Co Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2015
Bristol-Myers Squibb Co Investor Event: ASCO 2015 - 7:00PM EDT - Add to calendar
May 20, 2015
Bristol-Myers Squibb Co at UBS Global Healthcare Conference
May 12, 2015
Bristol-Myers Squibb Co at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Bristol-Myers Squibb Co at Deutsche Bank Health Care Conference
May 5, 2015
Bristol-Myers Squibb Co Annual Shareholders Meeting - Webcast
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Call
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Release
Mar 3, 2015
Bristol-Myers Squibb Co at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 29.67% 12.78%
Operating margin 31.90% 11.41%
EBITD margin - 24.69%
Return on average assets 14.29% 5.61%
Return on average equity 31.30% 13.36%
Employees 25,000 -
CDP Score - 98 B


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's products are sold across the world, to wholesalers, retail pharmacies, hospitals, Government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries. Its pharmaceutical products include chemically-synthesized drugs or small molecules, and products produced from biological processes. Its products in therapeutic classes: virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; metabolics; immunoscience, and cardiovascular. Its product F001287 is a preclinical, small-molecule IDO1-inhibitor. It offers an indoleamine 2, 3-dioxygenase (IDO) or tryptophan 2, 3-dioxygenase (TDO) discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries.

Officers and directors

Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Louis S Schmukler President - Global Manufacturing and Supply
Age: 59
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 53
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 54
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 49
Bio & Compensation  - Reuters
John E. Elicker Senior Vice President - Public Affairs
Age: 55
Bio & Compensation  - Reuters